Palatin Technologies Inc PTN

$6.49 -0.93 (-12.53%)

Valuation

Market cap
14,586,000
Revenue TTM
$13,190,000
Net income TTM
$-8,380,000
PE ratio
0.00
Forward PE
—
Profit margin
-63.53%
Debt to equity
0.00

Trading

Volume
43,383
Avg volume
78,072
Day's range
$6.35 – $8.00
Shares out
1,781,000
Stochastic %K
6%
Beta
0.63
Analysts
Strong Buy
Price target
$47.50

Price

Company profile

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanot...

Show more

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.

Industry
Biotechnology
Sector
Healthcare
Phone
609 495 2200
Website
https://palatin.com
Address
11 Deer Park Drive, Suite 204, Monmouth Junction, United States

Latest news

Stocktwits

Rayvio_News_Filter Oct 13, 1:43 PM
$PTN 🤝 On October 9, 2026, Cavitation Technologies, Inc. and Alchemy Beverages Inc. entered into definitive tender offer agreements with BrightFlixx Finance (Luxembourg) S.A., replacing Cavitation Technologies' prior August 14, 2026 tender offer agreement with European Guarantee Services S.à r.l. Selected from hundreds of headlines
1 replies
Ric_1M Oct 9, 11:47 AM
$VEEA $MI $FRGT $PTN $ALHC "When you genuinely accept the risks, you will be at peace with any outcome." Mark Douglas
0 replies
Jt11111 Sep 29, 12:26 PM
$PTN these guys are criminals
0 replies
EarningsInsider Sep 29, 6:03 AM
https://www.marketbeat.com/earnings/reports/2026-9-28-palatin-technologies-stock/ $PTN Palatin Technologies Earnings Transcript
0 replies
Kernmantel Sep 28, 7:36 PM
$PTN It looks like Palatin is racing out in the peptide-patent gold rush. Given their size and capital reserves, this is an excellent way to exploit their expertise for maximum benefit. Much larger companies are going to start salivating over these pipelines.
0 replies
StocktwitsEarnings Sep 28, 1:00 PM
$PTN Q4 '26 Earnings Results & Recap Palatin reported fiscal Q4 2026 collaboration and license revenue of approximately $300K and net loss of $4.4M; FY2026 revenue was $13.2M and net loss was $8.4M.
0 replies
Rollercoaster22 Sep 28, 12:27 PM
$PTN @SportTrade They have removed "IND Q4". Now it's "ongoing IND" instead. That's vague. I will listen to the conference and hopefully we will get some information about why they removed Q4.
0 replies
focafoca99 Sep 28, 11:40 AM
$PTN shared FY2026 results, reporting $13.2M collaboration revenue and a net loss of $8.4M. https://www.rapidticker.com/news/ptn-palatin-reports-fiscal-year-2026-4ced5c
0 replies